CONRAY 30 (iothalamate meglumine) by Guerbet is clinical pharmacology following intravascular injection, conray is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. First approved in 1971.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
CONRAY 30 is an iodinated contrast medium (iothalamate meglumine) administered by injection for radiographic visualization in diagnostic imaging procedures. It works by rapidly distributing through the circulatory system and being excreted unchanged via glomerular filtration, creating radiographic density that permits visualization of blood vessels, organs, and structures during angiography and CT scanning. The drug crosses the blood-brain barrier minimally in normal tissue but accumulates in lesions, enabling contrast-enhanced brain imaging.
This legacy product is approaching loss of exclusivity with minimal linked job openings, indicating a contracted brand team focused on maintenance rather than growth initiatives.
CLINICAL PHARMACOLOGY Following intravascular injection, Conray is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. The pharmacokinetics of intravascularly administered radiopaque contrast media are usually best…
Worked on CONRAY 30 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CONRAY 30 offers limited career growth potential given the approaching LOE and zero active job postings; roles are primarily in product maintenance and compliance rather than innovation or launch. Career mobility is best pursued by transitioning to growth-stage products within Guerbet's portfolio before organizational restructuring occurs.